ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor, Mediates Antitumor Efficacy Through Distinct Mechanisms in Two Prostate Cancer Xenograft Models
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Shortcuts Open/Close/ or ?
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor, Mediates Antitumor Efficacy Through Distinct Mechanisms in Two Prostate Cancer Xenograft Models
Date
June 21, 2021
Speaker
Aleksandr Pankov, PhD
ORIC Pharmaceuticals